Carlos García Girón-rekin lankidetzan egindako argitalpenak (7)

2012

  1. Changes in the levels of thioredoxin and indoleamine-2,3-dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy

    Biochemistry and Cell Biology, Vol. 90, Núm. 2, pp. 173-178

2011

  1. KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer

    Molecular Biology Reports, Vol. 38, Núm. 2, pp. 1315-1320

  2. PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population

    Molecular Biology Reports, Vol. 38, Núm. 2, pp. 1347-1351

2010

  1. No evidence for JAK2 V617F mutation in colorectal cancer

    British Journal of Biomedical Science, Vol. 67, Núm. 4, pp. 220-222

  2. TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status

    Journal of Translational Medicine, Vol. 8

2008

  1. Análisis mutacional de k-ras en carcinoma colorrectal metastasico. Implicaciones terapéuticas.

    Revista Electrónica de Biomedicina, Núm. 1, pp. 3-5

  2. Expresión del receptor de factor de crecimiento epidérmico (egfr) en el carcinoma colorrectal primario y metastásico.

    Revista Electrónica de Biomedicina, Núm. 1, pp. 43-53